Skip to content
Advertisement

This image provided by Novartis shows Rydapt. The Food and Drug Administration on Friday approved Rydapt for treating adults newly diagnosed with acute myeloid leukemia who have a genetic mutation called FLT3. Patients would take it along with chemotherapy.The drug, known chemically as midostaurin, is the first new medicine for acute myeloid leukemia in 25 years, according to the company. (Novartis via AP)

This image provided by Novartis shows Rydapt. The Food and Drug Administration on Friday approved Rydapt for treating adults newly diagnosed with acute myeloid leukemia who have a genetic mutation called FLT3. Patients would take it along with chemotherapy.The drug, known chemically as midostaurin, is the first new medicine for acute myeloid leukemia in 25 years, according to the company. (Novartis via AP)

Featured Photo Galleries